EGFR Mutation
15 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE) (NCT05465343) | Peking Union Medical College | 2022-07-11 |
| First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) (NCT05099172) | Bayer | 2021-10-25 |
| Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation (NCT03486496) | Fujian Cancer Hospital | 2018-06-05 |
| Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer (NCT01951469) | Sun Yat-sen University | 2016-01-01 |
| Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients (NCT02226757) | Amsterdam UMC, location VUmc | 2014-08-01 |
| Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC (NCT02140333) | The First Affiliated Hospital of Guangzhou Medical University | 2013-08-01 |
Track EGFR Mutation automatically
Every clearance here is in the API, with alerts when new ones post.